Tibotec’s Etravirine NNRTI For HIV NDA Has Jan. 18 Action Date
J&J subsidiary's non-nucleoside reverse transcriptase inhibitor was granted priority review by FDA.
J&J subsidiary's non-nucleoside reverse transcriptase inhibitor was granted priority review by FDA.